Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Language
Year range
1.
Article in English | IMSEAR | ID: sea-40211

ABSTRACT

OBJECTIVE: To evaluate the outcome of genetic amniocentesis in twin gestations at Songklanagarind Hospital. MATERIAL AND METHOD: This was a descriptive study that included all women with twin pregnancies who had a second trimester amniocentesis for chromosome study at the Maternal Fetal Medicine Unit, Department of Obstetrics and Gynecology, Songklanagarind Hospital from January 1998 through June 2006 to assess the outcome including risk of fetal loss in such cases. RESULTS: Advanced maternal age was the most common indication for amniocentesis. The success rate of cell culture was 100%. The fetal loss within 14 days after the procedure was 1.4%. CONCLUSION: The tendency of fetal loss after amniocentesis in twin pregnancies was higher than in singletons. Pre-procedure counseling personnel should be aware of this potential outcome, and be sure to inform the involved parents prior to the procedure.


Subject(s)
Adult , Amniocentesis/adverse effects , Female , Fetal Death , Gestational Age , Humans , Maternal Age , Middle Aged , Pilot Projects , Pregnancy , Pregnancy Outcome , Pregnancy Trimester, Second , Twins
2.
Article in English | IMSEAR | ID: sea-37747

ABSTRACT

Primary malignant lymphoma of the cervix is a rare disease. Because the number of reports of this cancer is limited, there is no consensus on its management, prognosis or the efficacy of various treatments. Primary malignant lymphoma of the cervix stage Ib was diagnosed in a 25-year-old woman. The patient was treated with 6 courses of CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone). Clinical and pathological responses were complete. This case supports current thinking in that, in selected young patients with primary malignant lymphoma of the cervix who desire to preserve fertility and ovarian functions, combination chemotherapy regimens such as CHOP are the treatment of choice.


Subject(s)
Adult , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cyclophosphamide/therapeutic use , Doxorubicin/therapeutic use , Female , Humans , Lymphoma, Non-Hodgkin/complications , Prednisone/therapeutic use , Uterine Cervical Neoplasms/complications , Vincristine/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL